From the Editor
Ambition is overrated. The ambitious find it harder to accept failure, and some degree of failure is likely.
Research published by Washington University’s Center for Advanced Studies in Adaptive Systems (CASAS) describes a technology that aims to help...
Tumor marker assessment in the surveillance period may be more of a hindrance than a help.
Applying research to practice
Dr. Alan P. Lyss highlights two articles that demonstrate the safety of established treatments – nephrectomy and stereotactic ablative body...
Dr. Stephen S. Grubbs, of the American Society of Clinical Oncology, discusses the future of the Oncology Care Model and other options for value-...
Law & Medicine
Health care fraud, waste, and abuse consume some 10% of federal health expenditures.
Dr. Richard W. Cohen describes how his experience as a patient changed his perspective on practicing medicine.
Black women report symptoms less, have more delays in diagnosis, and experience more frequent deviations from guideline-directed diagnostics.
A reference guide for the latest drug approvals in hematology and oncology, including biosimilars.
Law & Medicine
The plaintiff will typically be disqualified from offering medical testimony, unless there is “common knowledge.”
USPSTF recommendations on risk assessment, genetic counseling, and genetic testing for BRCA-related cancer
They recommend using screening tools focusing on family history that primary care physicians can utilize to determine who should be referred for...